Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 331

1.

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.

Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Review.

PMID:
19758759
2.

Predicting anthracycline benefit: have we made any progress?

Moretti E, Oakman C, Di Leo A.

Curr Opin Oncol. 2009 Nov;21(6):507-15. doi: 10.1097/CCO.0b013e328331a501. Review.

PMID:
19713842
3.

Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.

Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Breast. 2008 Oct;17(5):506-11. doi: 10.1016/j.breast.2008.03.007. Epub 2008 May 5.

PMID:
18456496
4.
5.

Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.

Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D.

Breast Cancer Res Treat. 2003 Feb;77(3):199-204.

PMID:
12602919
6.
7.

Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.

Clin Cancer Res. 2002 Apr;8(4):1061-7.

8.

The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.

Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.

Breast Cancer Res Treat. 2011 Oct;129(3):839-48. doi: 10.1007/s10549-011-1694-9. Epub 2011 Aug 2.

PMID:
21809115
9.

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.

Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.

Breast Cancer Res Treat. 2005 Jul;92(1):69-75.

PMID:
15980993
10.

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D.

Eur J Cancer. 2008 Dec;44(18):2791-8. doi: 10.1016/j.ejca.2008.09.014. Epub 2008 Nov 5. Review.

PMID:
18993056
11.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
12.
13.

Anthracycline war: no victor yet.

Young P.

J Natl Cancer Inst. 2009 Sep 2;101(17):1171-3. doi: 10.1093/jnci/djp303. Epub 2009 Aug 25. No abstract available.

PMID:
19706625
14.

Topoisomerase 2 alpha and the case for individualized breast cancer therapy.

Glynn RW, Miller N, Whelan MC, Kerin MJ.

Ann Surg Oncol. 2010 May;17(5):1392-7. doi: 10.1245/s10434-009-0855-0. Epub 2010 Mar 9.

PMID:
20217261
15.
16.

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.

Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.

Hum Pathol. 2010 Nov;41(11):1617-23. doi: 10.1016/j.humpath.2010.04.013. Epub 2010 Aug 4.

PMID:
20688355
17.

Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.

Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP.

Eur J Cancer. 2006 Nov;42(17):2954-60. Epub 2006 Aug 28.

PMID:
16935488
18.

HER-2, TOP2A and chromosome 17 alterations in breast cancer.

Beser AR, Tuzlali S, Guzey D, Dolek Guler S, Hacihanefioglu S, Dalay N.

Pathol Oncol Res. 2007;13(3):180-5. Epub 2007 Oct 7.

19.

Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?

Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, Gerber B, Braun S, Sommer H, Friese K.

J Cancer Res Clin Oncol. 2005 Aug;131(8):539-46. Epub 2005 May 11.

PMID:
15887027
20.

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A.

Int J Oncol. 2004 Jan;24(1):201-9.

PMID:
14654958

Supplemental Content

Support Center